When it comes to the insulin market Afrezza has always been lost in the shuffle. The problem with Afrezza has never been whether it works the problem has always been and continues to be getting Afrezza into the hands of patients. As MannKind noted during their earnings call yesterday they face some very high hurdles. Lilly, Novo Nordisk and Sanofi have substantial resources at their disposable and MannKind just can’t compete with that.
Therefore, the company must refocus their efforts and begin to transform from a diabetes company to a drug delivery company. This transformation will involve several steps . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.